(Recorded on January 22, 2015)
The impact of the implementation of Studylog Animal Study Workflow Software in a pharmaceutical company will be discussed from the perspective of a long-term user. Functionality highlights will be shown and the differences relative to Spreadsheets, LIMS and ELNs will be explained.
- Learn about the actual, real-world impact of study software on work capacity, quality and scheduling oversight.
- Better understand the functional possibilities of Animal Study Workflow Software.
- Learn how Studylog Software fills gaps currently unmet by Electronic Lab Notebooks and LIMS Systems.
- Learn about the financial impacts of implementation and use of Animal Study Workflow Software.
Ingrid Joseph DVM., PhD
Senior Director, Pharmacology and Bioimaging, Agensys Inc. email@example.com
At Agensys, (a wholly owned subsidiary of Astellas Pharma), Ingrid Joseph DVM., PhD, is responsible for supporting cancer biotherapeutic drug discovery and development. She has more than 20 years of experience in both small molecule and therapeutic antibody drug discovery and development in Oncology, including leading the advancement of potential cancer therapies into clinical testing. Ingrid is an OncoPharmacologist with experience in developing patient derived tumor models and companion diagnostics. Prior to joining Agensys in 2011, Ingrid held scientific management positions at Biogen Idec and Abbott Laboratories. She received her Oncology training at the Johns Hopkins Oncology Center. Subsequently, at the Oncology Center, she did research on tumor angiogenesis and evaluated immunomodulatory and anti-angiogenic cancer therapeutics.
Vice President, Studylog Systems, Inc. firstname.lastname@example.org
Eric Ibsen co-founded Studylog Systems in 2003, bringing to Studylog extensive international experience in, pharmacology, animal modeling, toxicology and quality assurance in the biopharmaceutical industry. At PDL BioPharma, Ibsen conducted essential in vivo research in toxicology, oncology, inflammation and animal model development. Ibsen contributed to a successful drug discovery effort in oncology as a Scientist at Eos Biotechnology. From 1983 to 2001 he performed pharmacology research in a variety of organizations, including the Stehlin Foundation for Cancer Research, Cetus Corporation, XOMA Corporation, Bayer AG (Germany), Genentech and Theravance.